| pubmed-article:15606399 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15606399 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15606399 | lifeskim:mentions | umls-concept:C0010674 | lld:lifeskim |
| pubmed-article:15606399 | lifeskim:mentions | umls-concept:C0267963 | lld:lifeskim |
| pubmed-article:15606399 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:15606399 | lifeskim:mentions | umls-concept:C0724055 | lld:lifeskim |
| pubmed-article:15606399 | pubmed:issue | 11-12 | lld:pubmed |
| pubmed-article:15606399 | pubmed:dateCreated | 2004-12-20 | lld:pubmed |
| pubmed-article:15606399 | pubmed:abstractText | Cystic fibrosis causes exocrine pancreatic insufficiency, leading to malabsorption. Supplemental pancreatic enzyme therapy alleviates the concomitant malnutrition experienced by cystic fibrosis patients. It is recognized that patients experience variations in clinical response to different brands of enzymes. This has prompted the US Food and Drug Administration to require that enzyme supplements be subjected to New Drug Applications. | lld:pubmed |
| pubmed-article:15606399 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15606399 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15606399 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15606399 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15606399 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15606399 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15606399 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15606399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15606399 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15606399 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15606399 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:15606399 | pubmed:issn | 0269-2813 | lld:pubmed |
| pubmed-article:15606399 | pubmed:author | pubmed-author:SternR CRC | lld:pubmed |
| pubmed-article:15606399 | pubmed:author | pubmed-author:ColinPP | lld:pubmed |
| pubmed-article:15606399 | pubmed:author | pubmed-author:ShermanJ MJM | lld:pubmed |
| pubmed-article:15606399 | pubmed:author | pubmed-author:EigenHH | lld:pubmed |
| pubmed-article:15606399 | pubmed:author | pubmed-author:TroutJ RJR | lld:pubmed |
| pubmed-article:15606399 | pubmed:author | pubmed-author:WagenerJ SJS | lld:pubmed |
| pubmed-article:15606399 | pubmed:author | pubmed-author:DugganCC | lld:pubmed |
| pubmed-article:15606399 | pubmed:author | pubmed-author:KonstanM WMW | lld:pubmed |
| pubmed-article:15606399 | pubmed:author | pubmed-author:WohlM E BME | lld:pubmed |
| pubmed-article:15606399 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15606399 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:15606399 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15606399 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15606399 | pubmed:pagination | 1365-71 | lld:pubmed |
| pubmed-article:15606399 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:15606399 | pubmed:meshHeading | pubmed-meshheading:15606399... | lld:pubmed |
| pubmed-article:15606399 | pubmed:meshHeading | pubmed-meshheading:15606399... | lld:pubmed |
| pubmed-article:15606399 | pubmed:meshHeading | pubmed-meshheading:15606399... | lld:pubmed |
| pubmed-article:15606399 | pubmed:meshHeading | pubmed-meshheading:15606399... | lld:pubmed |
| pubmed-article:15606399 | pubmed:meshHeading | pubmed-meshheading:15606399... | lld:pubmed |
| pubmed-article:15606399 | pubmed:meshHeading | pubmed-meshheading:15606399... | lld:pubmed |
| pubmed-article:15606399 | pubmed:meshHeading | pubmed-meshheading:15606399... | lld:pubmed |
| pubmed-article:15606399 | pubmed:meshHeading | pubmed-meshheading:15606399... | lld:pubmed |
| pubmed-article:15606399 | pubmed:meshHeading | pubmed-meshheading:15606399... | lld:pubmed |
| pubmed-article:15606399 | pubmed:meshHeading | pubmed-meshheading:15606399... | lld:pubmed |
| pubmed-article:15606399 | pubmed:meshHeading | pubmed-meshheading:15606399... | lld:pubmed |
| pubmed-article:15606399 | pubmed:meshHeading | pubmed-meshheading:15606399... | lld:pubmed |
| pubmed-article:15606399 | pubmed:meshHeading | pubmed-meshheading:15606399... | lld:pubmed |
| pubmed-article:15606399 | pubmed:meshHeading | pubmed-meshheading:15606399... | lld:pubmed |
| pubmed-article:15606399 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15606399 | pubmed:articleTitle | Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy. | lld:pubmed |
| pubmed-article:15606399 | pubmed:affiliation | Rainbow Babies and Children's Hospital, Cleveland, OH 44106, USA. michael.konstan@case.edu | lld:pubmed |
| pubmed-article:15606399 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15606399 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15606399 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:15606399 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:15606399 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:15606399 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15606399 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:15606399 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:15606399 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| pubmed-article:15606399 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15606399 | lld:pubmed |
